Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Other Non-Current Assets (2017 - 2025)

Historic Other Non-Current Assets for Puma Biotechnology (PBYI) over the last 9 years, with Q3 2025 value amounting to $2.1 million.

  • Puma Biotechnology's Other Non-Current Assets fell 578.73% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 578.73%. This contributed to the annual value of $2.1 million for FY2024, which is 2318.95% down from last year.
  • Puma Biotechnology's Other Non-Current Assets amounted to $2.1 million in Q3 2025, which was down 578.73% from $2.1 million recorded in Q2 2025.
  • Over the past 5 years, Puma Biotechnology's Other Non-Current Assets peaked at $12.2 million during Q1 2021, and registered a low of $2.1 million during Q4 2024.
  • In the last 5 years, Puma Biotechnology's Other Non-Current Assets had a median value of $2.6 million in 2022 and averaged $4.6 million.
  • As far as peak fluctuations go, Puma Biotechnology's Other Non-Current Assets tumbled by 7868.85% in 2022, and later soared by 1184.62% in 2023.
  • Puma Biotechnology's Other Non-Current Assets (Quarter) stood at $12.2 million in 2021, then tumbled by 78.69% to $2.6 million in 2022, then grew by 5.15% to $2.7 million in 2023, then dropped by 23.19% to $2.1 million in 2024, then changed by 0.0% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.1 million for Q2 2025, and $2.1 million during Q1 2025.